Zonisamide
FDA-approved product (capsule, oral), marketed as Zonegran, Zonisade, Zonisamide.
- Registered studies
- 50+
- Lab records
- 1
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Epilepsy
- Focal-onset seizure
- Partial epilepsy
- Seizure
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antiepileptics
- FDA pharmacologic class
- Anti-epileptic Agent FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli12.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae7.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis82.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 1 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Zonisamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
NCT01713946 · start 2013-04-29
Registered record
- Registry ID
- NCT01713946
- Conditions
- Tuberous Sclerosis Complex-associated Refractory Seizures
- Interventions
- RAD001; Placebo; Antiepileptic drug (1 to 3 only); open label RAD001 (only used for post-extension phase)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-04-29
- Completion
- 2017-10-25
- Enrolment
- 366
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberous Sclerosis Complex-associated Refractory SeizuresInterventionRAD001; Placebo; Antiepileptic drug (1 to 3 only); open label RAD001 (only used for post-extension phase)PhasePhase 3Registry statusCompletedStudy of Zonisamide in Early Parkinson Disease
NCT01766128 · start 2013-02
Registered record
- Registry ID
- NCT01766128
- Conditions
- Parkinson Disease
- Interventions
- Zonisamide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Withdrawn
- Start
- 2013-02
- Completion
- 2013-02
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson DiseaseInterventionZonisamide; PlaceboPhasePhase 2 / Phase 3Registry statusWithdrawnZonisamide Augmentation of Varenicline Treatment for Smoking Cessation
NCT01685996 · start 2012-09
Registered record
- Registry ID
- NCT01685996
- Conditions
- Nicotine Dependence
- Interventions
- zonisamide; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2014-05
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNicotine DependenceInterventionzonisamide; placeboPhasePhase 1 / Phase 2Registry statusCompletedA Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
NCT01830868 · start 2012-03
Registered record
- Registry ID
- NCT01830868
- Conditions
- Partial Onset Seizures
- Interventions
- Zonisamide tablets
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2013-08
- Enrolment
- 104
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPartial Onset SeizuresInterventionZonisamide tabletsPhaseNot recordedRegistry statusCompletedEfficacy Trial of Zonisamide for Myoclonus Dystonia
NCT01806805 · start 2012-02
Registered record
- Registry ID
- NCT01806805
- Conditions
- Myoclonus Dystonia
- Interventions
- zonegran; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-02
- Completion
- 2014-07
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyoclonus DystoniaInterventionzonegran; placeboPhasePhase 3Registry statusCompletedSystematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
NCT01587339 · start 2010-09
Registered record
- Registry ID
- NCT01587339
- Conditions
- Epilepsy
- Interventions
- retigabine/ezogabine; lacosamide; zonisamide; pregabalin; eslicarbazepine
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2010-09
- Completion
- 2011-07
- Enrolment
- 6,498
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEpilepsyInterventionretigabine/ezogabine; lacosamide; zonisamide; pregabalin +1 morePhaseNot recordedRegistry statusCompletedEffect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse
NCT01137890 · start 2010-06
Registered record
- Registry ID
- NCT01137890
- Conditions
- Cocaine Dependence
- Interventions
- Zonisamide; Placebo; Cocaine Hydrochloride; Neurocognitive and Performance Battery; Smoking Assessments
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2010-06
- Completion
- 2013-08
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine DependenceInterventionZonisamide; Placebo; Cocaine Hydrochloride; Neurocognitive and Performance Battery +1 morePhasePhase 1 / Phase 2Registry statusCompletedClinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
NCT01390909 · start 2010-05
Registered record
- Registry ID
- NCT01390909
- Conditions
- Epilepsy
- Interventions
- Anti-epileptic drug (AED)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2010-05
- Completion
- 2011-01
- Enrolment
- 12,386
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEpilepsyInterventionAnti-epileptic drug (AED)PhaseNot recordedRegistry statusCompletedEvaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug
NCT01630057 · start 2009-09
Registered record
- Registry ID
- NCT01630057
- Conditions
- Partial Seizures
- Interventions
- Adjunctive Zonisamide; Replacement with Zonisamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2012-07
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPartial SeizuresInterventionAdjunctive Zonisamide; Replacement with ZonisamidePhasePhase 4Registry statusCompletedInterdisciplinary Study of Two Novel Anticonvulsants in Alcoholism
NCT00862563 · start 2009-05
Registered record
- Registry ID
- NCT00862563
- Conditions
- Alcoholism; Alcohol Dependence; Alcohol Abuse
- Interventions
- Topiramate; Zonisamide; Levetiracetam; Sugar Pill
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2009-05
- Completion
- 2013-08
- Enrolment
- 85
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlcoholism; Alcohol Dependence; Alcohol AbuseInterventionTopiramate; Zonisamide; Levetiracetam; Sugar PillPhasePhase 2Registry statusTerminatedEfficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
NCT00566254 · start 2008-12
Registered record
- Registry ID
- NCT00566254
- Conditions
- Epilepsy; Paediatric Partial Onset Seizures
- Interventions
- Zonisamide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2011-03
- Enrolment
- 207
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEpilepsy; Paediatric Partial Onset SeizuresInterventionZonisamide; PlaceboPhasePhase 3Registry statusCompletedAssessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
NCT00848549 · start 2008-10
Registered record
- Registry ID
- NCT00848549
- Conditions
- Epilepsy
- Interventions
- Zonisamide; Carbamazepine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2011-11
- Enrolment
- 295
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEpilepsyInterventionZonisamide; CarbamazepinePhasePhase 3Registry statusCompletedOlanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCT00734435 · start 2008-09
Registered record
- Registry ID
- NCT00734435
- Conditions
- Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
- Interventions
- zonisamide SR plus olanzapine; Placebo plus olanzapine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2008-09
- Completion
- 2008-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform DisorderInterventionzonisamide SR plus olanzapine; Placebo plus olanzapinePhasePhase 2Registry statusTerminatedAdjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
NCT00692003 · start 2008-08-01
Registered record
- Registry ID
- NCT00692003
- Conditions
- Epilepsy
- Interventions
- Zonisamide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2008-08-01
- Completion
- 2009-01-09
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEpilepsyInterventionZonisamide; PlaceboPhasePhase 3Registry statusTerminatedA Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
NCT00363376 · start 2008-01
Registered record
- Registry ID
- NCT00363376
- Conditions
- Weight Gain
- Interventions
- zonisamide; olanzapine; Zonisamide; Sugar Pill (placebo)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2011-02
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWeight GainInterventionzonisamide; olanzapine; Zonisamide; Sugar Pill (placebo)PhasePhase 3Registry statusCompleted